Induction of protective immunity against lethal anthrax challenge with a patch

Journal of Infectious Diseases

Volumn 190, Issue 4, 2004, Pages 774-782

  Kenney, Richard T ^a   Yu, Jianmei ^a   Guebre Xabier, Mimi ^a   Frech, Sarah A ^a   Lambert, Adam ^a   Heller, Barbara A ^a   Ellingsworth, Larry R ^a   Eyles, James E ^b   Williamson, E Diane ^b   Glenn, Gregory M ^a  

^a IOMAI Corporation   (United States)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIUM ANTIBODY;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; EVALUATION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRANSDERMAL PATCH; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; LYMPH NODES; MICE; NEUTRALIZATION TESTS; RABBITS; RECOMBINANT PROTEINS; TIME FACTORS; VACCINATION; VACCINES, SUBUNIT;

EID: 3943056060     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422694     Document Type: Article

References (35)

1. Spencer RC, Lightfoot NF. Preparedness and response to bioterrorism. J Infect 2001; 43:104-10.
2. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci USA 2003; 100:10129-32.
3. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. Anthrax vaccine: short-term safety experience in humans. Vaccine 2001; 20:972-8.
4. Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 1988; 177:293-303.
5. Leppla SH, Robbins JB, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. J Clin Invest 2002; 110:141-4.
6. Jendrek S, Little SF, Hem S, Mitra G, Giardina S. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 2003; 21:3011-8.
7. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6:1403-6.
8. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij PJ. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2003; 2:253-67.
9. Katz SL. Future vaccines and a global perspective. Lancet 1997; 350:1767-70.
10. Liu MA. Vaccine developments. Nat Med 1998; 4:515-9.
11. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 2000; 68:5306-13.
12. Godefroy S, Goestch L, Plotnicky-Gilquin H, et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). Vaccine 2003; 21:1665-71.
13. Güereña-Burgueño F, Hall ER, Taylor DN, et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002; 70:1874-80.
14. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin [letter]. Nature 1998; 391:851.
15. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998; 161:3211-4.
16. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67:1100-6.
17. Hammond SA, Tsonis C, Sellins K, et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 2000; 43:45-55.
18. Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 1988; 5:127-39.
19. Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986; 52:356-63.
20. McBride BW, Mogg A, Telfer JL, et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16:810-7.
21. Fellows PF, Linscott MK, Ivins BE, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19:3241-7.
22. Vasconcelos D, Barnewall R, Babin M, et al. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2003; 83:1201-9.
23. Beedham RJ, Turnbull PC, Williamson ED. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 2001; 19:4409-16.
24. Welkos SL, Friedlander AM. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog 1988;4:53-69.
25. Flick-Smith HC, Eyles JE, Hebdon R, et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 2002; 70:2022-8.
26. Yu J, Cassels F, Scharton-Kersten T, et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 2002; 70:1056-68.
27. Welkos S, Little S, Friedlander A, Fritz D, Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001; 147:1677-85.
28. Hartman AB, Van De Verg LL, Venkatesan MM. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect Immun 1999; 67:5841-7.
29. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth LR, Glenn GM. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 2003; 77:5218-25.
30. Little SF, Novak JM, Lowe JR, et al. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 1996; 142:707-15.
31. Food and Drug Administration. New drug and biological drug products: evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Regist 2002; 67:37988-98.
32. Matyas GR, Friedlander AM, Glenn GM, Little S, Yu J, Alving CR. Needle-free skin patch vaccination method for anthrax. Infect Immun 2004; 72:1181-3.
33. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170:5636-43.
34. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 1986; 52:509-12.
35. Pitt ML, Little SF, Ivins BE, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19:4768-73.